Compare Tempus AI (TEM) vs Zeta Global Holdings Corp (ZETA) Price & Performance

Tempus AI (TEM) trades at $54.48, down 1.05% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported a Q2 2026 loss of $0.04 per share, beating estimates, and raised 2026 revenue guidance to $1.4 billion. Recent news highlights growth in oncology testing and AI-driven precision medicine, including the planned acquisition of Personalis to expand minimal residual disease testing capabilities.

Outlook remains positive with 61.5% analyst buy ratings and a $61.57 consensus price target, though risks include persistent net losses, high cash burn from operations, and competitive pressures in AI healthcare. The stock offers upside if execution improves profitability, but investors should monitor cash flow sustainability and integration of acquisitions.

ZETA stock trades at $28.62, up 3.92% in the past 24 hours, with a bullish technical signal from moving averages and strong support at $28. The company reported its 20th consecutive beat-and-raise quarter in Q2 2026, with revenue up 44% year-over-year and achieving its first GAAP net income. Analyst consensus is strongly bullish with a $30.44 price target, and recent news highlights AI-driven growth and a partnership with Palantir.

The outlook for ZETA is positive due to robust revenue growth, expanding AI adoption, and improving profitability, but risks include a rich valuation with a P/S of 4.35 and EV/EBITDA of 95.89, execution challenges in integrating acquisitions, and competitive pressures in the marketing tech sector. The stock's proximity to its 52-week high suggests limited near-term upside without continued strong earnings performance.